Skip to main content
. Author manuscript; available in PMC: 2010 Jul 1.
Published in final edited form as: Leuk Res. 2009 Feb 20;33(7):937–947. doi: 10.1016/j.leukres.2009.01.018

Figure 3.

Figure 3

Treatment of KOPN-8 and RAJI cells with PFWT in combination with chemotherapeutic drugs induces a modest decrease in cell viability compared to treatment with PFWT or drugs alone. KOPN-8 cells were treated simultaneously (SIMT) with PFWT (μg/mL) and either 17AAG (nM), a Flt-3 Inhibitor (nM), cytarabine (nM) or etoposide (nM) for 72 h. RAJI cells were treated simultaneously (SIMT) with PFWT (μg/mL) and either 17AAG (nM) or a Flt-3 Inhibitor (nM) for 72 h. They were treated sequentially (SEQ) with PFWT (μg/mL) and either cytarabine (nM) or etoposide (nM) for 72 h. In sequentially treated cells (SEQ), cells were pretreated with either cytarabine or etoposide for 24 h followed by the addition of PFWT. Standard error of the mean (SEM) is represented by error bars. AraC = cytarabine; VP-16 = etoposide.